There are effective medications for opioid use disorder and alcohol use disorder, and none approved for cocaine or methamphetamine. Every treatment we have, and every one still needed, depends on the same pipeline: turning a biological discovery into a compound, a data package, and eventually a clinical trial. Preclinical addiction research is that pipeline’s engine.
Here is how the journey actually works.
Step 1: A target emerges
Treatments start with mechanism. A GWAS hit implicates a gene in addiction vulnerability. A single-cell study finds a receptor enriched in a neuronal population that drives withdrawal’s negative emotional state. A network analysis identifies a hub region reorganized in dependence. A behavioral analysis isolates a trait contributing to the vulnerability to addiction. Each is a candidate point of intervention, a target.
Step 2: Proof of concept in validated models
Next question: does engaging the target actually change addiction-like behavior? This is where validated animal models earn their keep (what models can and can’t tell us). A candidate compound is tested against the core behavioral endpoints:
- Does it reduce escalated drug intake in extended-access self-administration?
- Does it lower motivation (progressive-ratio breakpoints)?
- Does it reduce compulsive use (responding despite adverse consequences)?
- Does it block relapse-like behavior triggered by cues, stress, or the drug itself?
Testing across these endpoints matters because they engage different brain systems, a compound can block relapse without touching intake, or vice versa. Modern best practice also demands genetically diverse animals and attention to individual differences, so efficacy is not an artifact of one inbred genotype (Venniro et al., 2020).
Step 3: Mechanism verification
Regulators and pharmaceutical partners want to know a drug works for the reason claimed. Neuroscience tools, optogenetics, chemogenetics, in vivo electrophysiology, whole-brain activity mapping, verify that the compound engages its target and that the target sits in the circuit doing the behavioral work. This is the level of causal resolution that only preclinical research can provide.
Step 4: The pre-IND package
Before any first-in-human trial, the FDA requires an Investigational New Drug (IND) application: safety and toxicity data, pharmacokinetics (how the body absorbs and clears the compound), dose–response relationships, and efficacy evidence in validated models. Assembling this preclinical data package is a specialized craft, and a service our center’s investigators have contributed to for therapeutics ranging from small molecules to biologics and neuromodulation (preclinical testing services).
Step 5: Clinical trials, and reverse translation
If human trials succeed, a medication reaches patients. When they fail, as many have, the failures teach. The field’s response has been reverse translation: redesigning animal models to better mirror clinical reality, including choice between drug and alternative rewards, voluntary abstinence, and treatment during established addiction rather than before it (Venniro et al., 2020). The dialogue runs both directions, and the models keep improving.
Why centers matter here
No single lab spans this whole pipeline. A center structure, standardized behavioral phenotyping, genomics, imaging, biobanking, and pilot funding under one roof, lets a target move from discovery to a tested therapeutic hypothesis without leaving the building. That translational shortening is one of the core purposes of the Polysubstance Addiction Research Center.
References
- Venniro M, Banks ML, Heilig M, Epstein DH, Shaham Y (2020). Improving translation of animal models of addiction and relapse by reverse translation. Nature Reviews Neuroscience 21:625–643. PMID 33024318
- Volkow ND, Koob GF, McLellan AT (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine 374:363–371. PMID 26816013
- Ahmed SH, Koob GF (1998). Transition from moderate to excessive drug intake: change in hedonic set point. Science 282:298–300. PMID 9765157